ARTICLE | Company News
Astellas, AstraZeneca deal
January 2, 2012 8:00 AM UTC
Astellas' Prosidion Ltd. subsidiary granted AstraZeneca an exclusive option to acquire Type II diabetes compounds PSN821 and PSN842, both of which are G protein-coupled receptor 119 (GPR119) agonist...